RB-ADSC for Treatment of Mild to Moderate Alzheimer's Disease

This is a research study to evaluate the safety of an investigational autologous cell product obtained from participant's own adipose tissue as a possible treatment for Alzheimer disease.

Inclusion Criteria:≥45 and ≤80 years of ageMild to moderate AD diagnosisAdequate cognitive functionNon-remarkable clinical laboratoryAbility to voluntarily provide written informed consentNo tumors or other disease responsible for dementiaWell-controlled comorbidities, on stable medications for 3 monthsThe participant is otherwise in good general healthThe participant must have a relative/caregiverParticipant must be able to donate adequate amount of lipoaspirate to establish the final productCaregiver separately meets the specified inclusion/exclusion criteria for caregiversExclusion Criteria:Taking other medications for AD, except that donepezil memantine, AChEIs including patches, Vitamin E, fish oil, and/or gingko biloba are allowed if doses have been stable for at least 3 months prior to the Screening visitStem cell implantation of any type within 3 monthsExisting ventriculoperitoneal shuntsNeurological disorders except ADPsychiatric disorders including schizophrenia, bipolar/unipolar depressive disorder, deliriumDrug or alcohol abuse or dependence within the past 5 yearsParticipants with a history of cancer in the past 5 yearsNo caregiver available to meet the inclusion criteria for caregivers